Cargando…
Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
BACKGROUND: New first-line drug regimens for treatment of tuberculosis (TB) are in clinical trials: emergence of resistance is a key concern. Because population-level data on resistance cannot be collected in advance, epidemiological models are important tools for understanding the drivers and dyna...
Autores principales: | Shrestha, Sourya, Knight, Gwenan M., Fofana, Mariam, Cohen, Ted, White, Richard G., Cobelens, Frank, Dowdy, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281792/ https://www.ncbi.nlm.nih.gov/pubmed/25734143 http://dx.doi.org/10.1093/ofid/ofu073 |
Ejemplares similares
-
A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis
por: Fofana, Mariam O., et al.
Publicado: (2017) -
Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis
por: Fofana, Mariam O., et al.
Publicado: (2014) -
The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa
por: Knight, Gwenan M., et al.
Publicado: (2015) -
Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis
por: Hanrahan, Colleen F., et al.
Publicado: (2016) -
Mathematical Modeling of “Chronic” Infectious Diseases: Unpacking the Black Box
por: Fojo, Anthony T, et al.
Publicado: (2017)